Abstract The MAGhaler (Mundipharma GmbH) is a multidose dry powder inhaler (DPI) containing a novel formulation of drug and lactose compacted by an isostatic pressing technique (GGU GmbH). On actuation, a precise dose is metered from a compacted ring-shaped drug tablet. In this study, the lung deposition of salbutamol from this device has been assessed.Ten healthy non-smoking subjects completed a two-way cross-over study, assessing the pulmonary deposition of salbutamol (200 mg) from the MAGhaler at high (60 l/min) and low (30 l/min) peak inhaled flow rates (PIFRs), representing maximal and sub-maximal inspiratory efforts.The formulation was radiolabelled with 99m Tc, and lung and oropharyngeal depositions were quantified bygamma scintigraphy.The mean (SD)% ofthe delivered dose depositedinthe lungs was 26.4 (4.3)% at 60 l/min and 21.1 (5.1)% at 30 l/min (Po0.05), corresponding to mean lung depositions of 52.8 and 42.2 mg salbutamol, respectively.The distribution of drug within different lung regions did not vary significantly with inhaled flow rate.The data provided proof of concept for the novel inhaler device and the innovative drug formulation. In comparison with previous deposition data obtained with other DPIs, the lung deposition was relatively high, relatively reproducible (coefficient of variation 16% at 60 l/min) and relatively insensitive to the change in peak inhaled flow rate.
INTRODUCTION
The pressurised metered dose inhaler (pMDI) has been the most important inhaler device for the delivery of asthma drugs over several decades, but following the ban placed upon the production of chloro£uorocarbon (CFC) propellants by the Montreal Protocol (1), there has been much interest in the development of alternative inhaler technologies. Dry powder inhalers (DPIs) were ¢rst introduced almost 30 years ago (2) , but until relatively recently the available devices were single-dose units, with the drug contained in gelatine capsules. Several multidose DPIs are now available, with the drug either metered from a reservoir of free£owing powder (3), or contained in individually ¢lled blisters (4) .
Micronised powders are highly sensitive to atmospheric factors (for instance moisture, electrostatic charge and oxidation), which may reduce both ¢ne particle dose and dosage accuracy (5) . Several new ''next generation'' DPIs have been designed to deliver a more reliable and reproducible dose. The MAGhaler (Mundipharma GmbH, Fig. 1 ) ''Mechanical Aerosol Generator'' device contains a novel powder formulation, in which a blend of drug and lactose is compacted into a ring-tablet using a specially developed radial isostatic pressing technique (GGU GmbH) before being assembled into the inhaler. The device includes a mechanically wound drive unit intended for long-term use, incorporating a grinding wheel with a face-cutter.When the patient presses a button to actuate the device, an accurately metered dose of drug is milled from the front surface of the ring-tablet, and the patient's inhalation is then used to deliver the powder to the respiratory tract. In this study, a formulation of salbutamol has been radiolabelled with the radionuclide 99m Tc, so that its deposition in the human respiratory tract could be assessed by gamma scintigraphy (6) .The e¡ects of inhaling at fast and slow inhaled £ow rates, representing maximal and submaximal inspiratory e¡orts respectively, were compared.
MATERIALS AND METHODS

Study design
Ten healthy non-smoking volunteers (7 male, 3 female, aged 25^56 years), all with forced expiratory volume in 1s (FEV 1 ) 480% of the predicted value for their age, sex and height (7) took part in the study. Each subject gave written consent to the investigation, following an explanation of the study both verbally and in writing. The Quorn Research Review Committee (Leicestershire, U.K.) gave permission for the study to be performed, and the administration of radioactivity to the subjects was approved by the Department of Health, U.K. The study was conducted in accordance with the Declaration of Helsinki. The study was a randomised two-way cross-over investigation with a minimum of 48 h between each study leg. On each study day, subjects inhaled, in rapid succession, two 100 mg doses of salbutamol (total 200 mg) using either maximal inspiratory effort (targeted peak inhaled £ow rate, PIFR, 60 l/min) or a sub-maximal inspiratory e¡ort (targeted PIFR 30 l/ min).
Manufacture of radiolabelled formulations
A highly compacted ring-shaped tablet containing salbutamol, lactose and 99m Tc was manufactured on each study day.The method used to radiolabel the formulation was based partly upon that applied previously to other drug/lactose blends (8) . Approximately 10 GBq 99m Tc was dissolved in a non-aqueous solvent before being added to micronised salbutamol (0.170 g). After evaporation of the solvent, the radiolabelled salbutamol was blended with lactose (2.132 g) using a purpose-built mini-mixing device (GGU GmbH). The powder blend was then compressed isostatically (CIP 1000 isostatic press, ABB Industries) at a pressure of 152 MPa, to give a ring-tablet of density1.32 g/cm 3 .The ring-tablet was then assembled into a MAGhaler device. Each dose contained 100 mg salbutamol and approximately 1.2 mg lactose. Suf¢cient 99m Tc was used to ensure that following a period of radioactive decay between manufacture and dosing, each dose contained a maximum 5 MBq in the clinical study.
Radiolabelling validation
In order to demonstrate the quality of the radiolabelling, validation experiments were carried out in advance of the study days themselves (9, 10) , involving a series of radiolabelled and non-radiolabelled salbutamol formulations. The particle size distributions of drug before labelling (n=4), drug after labelling (n=6) and radiolabel (n=6) were obtained using a 5 -stage high-precision multistage liquid impinger (HPMLI, Copley Instruments, Nottingham, U.K.) operating at 60 l/min.The stages were washed with methanol, and drug recovered from each stage was assayed by ultraviolet spectroscopy. 99m Tc radiolabel recovered from each stage was quanti¢ed by gamma counting. The ¢ne particle fractions (FPFs) of drug and radiolabel (percentages of drug or radiolabel recovered from stages 3^5 of the impinger) were calculated as percentages of delivered dose. The study inhalers used on the study days were also assessed before the subjects were dosed in order to ensure that the FPFs of the radiolabel were comparable to the range of values seen in the pre-study validation experiments.
Measurement of delivered dose
The delivered dose of salbutamol from the MAGhaler was measured at £ow rates of both 60 and 30 l/min. A series of10 successive doses were taken from each of two non-radiolabelled MAGhalers, and were extracted into a unit dose sampling apparatus at the required £ow rate. The amount of drug collected in the sampling apparatus was quanti¢ed by high-performance liquid chromatography.
Administration of radiolabelled salbutamol powder
The radiolabelled drug formulation was administered with the inhaler device connected in series with a Vitalograph pMDI-Compact Spirometer (Vitalograph Ltd., Maids Moreton, U.K.), so that the inhalation £ow and inhalation volume could be determined. The spirometer displayed inhaled £ow rate vs. time on a screen which subjects could see as they inhaled, and they were instructed to keep the PIFR between a set of ''tram lines'' on the screen, set between 50 and 70 l/min for a targeted value of 60 l/min, and between 20 and 40 l/min for a targeted value of 30 l/min. Following each inhalation, subjects were instructed to hold their breath for 10 s and then exhale into a ¢lter. Once the subject had practiced the inhalation manoeuvre with a blank device, and had achieved the required inhalation technique reproducibly, the blank device was replaced with a device containing the radiolabelled formulation. In order to minimise the duration of the dosing procedure, only the inhalation details from the second of the two doses on each study day were recorded.
In vivo measurements
Scintigraphic images of the chest (posterior and anterior, duration 100 s), lateral oropharynx (duration 30 s), and exhalation ¢lter were recorded immediately after inhalation by gamma camera (General Electric Maxicamera, Madison, WI, U.S.A.), connected to a Park Medical Micas V data processing system (Farnborough, U.K.). A posterior lung ventilation scan was performed on one study day using the radioactive inert gas 81m Kr, and the lung outlines from the ventilation scan were used to de¢ne the lung borders on the aerosol views.The lungs were subdivided into three zones (central, intermediate and peripheral zones) representing primarily large, medium and small diameter airways, respectively (11) . Regions of interest were also drawn around the oropharynx, oesophagus and stomach, and the geometric means of anterior and posterior lung, oesophagus and stomach counts were calculated.Counts were corrected for background radioactivity, radioactive decay, and for the attenuation of gamma rays by overlying tissues (12) . The corrected counts from lungs, oropharynx (including oesophagus and stomach) and exhaled air ¢lter were summed, and percentage of the delivered dose located at each site was calculated by expressing the count recorded from each site as a percentage of the total count. The mouthpiece of the inhaler device could not be removed, so it was not possible to quantify retention of the dose on the device itself. The lung deposition data were expressed for each subject as mass of salbutamol by multiplying the percentage lung deposition ¢gures by the mean delivered dose.
Spirometric tests of lung function [FEV 1 , forced vital capacity (FVC) and peak exhaled £ow (PEF)] were measured before inhalation, and 30 minutes later (Microloop Spirometer, MicroMedical, Rochester, U.K.).
Statistical analysis
The Wilcoxon matched-pairs signed ranks test was used to determine whether di¡erences between the deposition patterns for the two £ow rates were signi¢cant. A P value of o0.05 was taken to indicate statistical signi¢-cance.
RESULTS
Radiolabelling validation
The results of the radiolabelling validation data are shown inTable 1.The mean FPFs for drug before labelling, drug after labelling and radiolabel were 46.7, 49.3 and 39.9% of the delivered dose. Although the lower FPF for radiolabel suggested that lung deposition might be slightly underestimated in an in vivo scintigraphic study, the radiolabelling method was considered suitable for use. The radiolabel FPFs for the inhalers used on the two study days on which subjects were dosed were 41.9 and 41.2 (mean 41.6%, Table 1 ).
Delivered dose data
In vitro tests showed that the mean (SD) delivered dose of salbutamol per shot was 101.7 (9.0) and 98.3 (8.1) mg for 2 inhalers at 60 l/min, and 98.1 (9.3) and 101.9 (7.4) mg salbutamol for 2 inhalers at 30 l/min ( Table 2 ).The actual delivered dose from two shots was therefore assumed to be identical to the nominal value of 200 mg at both £ow rates.
In vivo data
The fractionation of the delivered dose between lungs, oropharynx and exhaled air is shown in .5 l). There were no signi¢cant changes in any lung function parameter following inhalation of the radiolabelled formulation. FEV 1 averaged 3.89 (0.62) l before dosing, and 3.95 (0.65) l after dosing, at the fast £ow rate.The corresponding values at the slow £ow rate were 3.86 (0.65) l and 3.87 (0.69) l before and after dosing.
DISCUSSION
For many years, pMDIs have been the most widely used type of asthma inhaler. Until very recently, pMDIs have used CFC propellants to form the spray, but CFCs have been implicated in causing damage to the ozone layer, leading to a ban on their production throughout most of the world (1). While some companies have reformulated their pMDIs with alternative ozone-friendly propellants (13, 14) , others have developed alternative delivery systems. These have included DPIs, in which metered amounts of drug powder are dispersed into the inhaled airstream, usually by the patient's own inspiratory e¡ort (2, 15) . One of the additional bene¢ts of these ''breath-actuated'' devices is that the patient does not have to coordinate ¢ring the device with inhalation, a problem associated with sub-optimal drug delivery using pMDIs. However, a related disadvantage of breath-actuated DPIs is that drug deliveryin vivo can be a¡ected by the patient's PIFR, and hence upon the degree of inspiratory e¡ort that each patient is willing or able to expend.
Traditional DPIs contain either discrete blisters or capsules of powder, or dispense doses as freely £owing powder from a reservoir (15) . The MAGhaler device differs in that the powder is contained within the device in a highly compacted ring-shaped tablet, formed by a radial isostatic compression process. The dose is metered by the action of a blade, which mills an exact quantity of powder from the compacted block, prior to inhalation by the patient. This type of system has potential advantages in terms of highly reproducible dosing, and protection of the powder from the e¡ects of environmental moisture until the dose has been cut from the ring-tablet (Mundipharma, data on ¢le). Isostatic compression ensures that there is no compression gradient through the tablet, hence improving dose reproducibility throughout the life of the inhaler. Density variations within the tablet are less than 0.01%, enabling highly reproducible dosing to be achieved (GGU GmbH, data on ¢le).
One of the key issues in gamma scintigraphic studies is the validation of the radiolabelling method, in which it is required to show that the drug and radiolabel are distributed in the same manner through di¡erent particle size bands. This permits the radioactive counts to be used to quantify where drug has been deposited. The FPF of drug before the labelling process was 46.7% of the emitted dose, and the FPFs of the radiolabel on the two study days averaged 41.6%. Although these data were only obtained in a small number of replicate experiments, they represented a small mismatch between drug and radiolabel, and suggested that the lung deposition in vivo may have been slightly underestimated. A ''corrected'' value of lung deposition may be obtained by multiplying the measured whole lung depositions by the factor 46.7/41.6, i.e. 1.12. This calculation results in corrected mean whole lung deposition values of 29.6 and 23.7% of the delivered dose at PIFRs of 60 and 30 l/min, respectively. The coe⁄cient of variation of lung deposition (C of V, standard deviation expressed as a percentage of the mean) was 16% at a PIFR of 60 l/min.
When the PIFR was reduced from 60 to 30 l/min, lung deposition fell from a mean 26.4% to a mean 21.1% of the delivered dose. Although statistically signi¢cant, this fall in lung deposition was numerically small, and probably not clinically signi¢cant. As the delivered dose from the device was essentially independent of inhaled £ow rate, the di¡erence in lung depositions between the two inhaled £ow rates remained small when the data were expressed as mass of salbutamol deposited in the lungs (52.8 mg vs. 42.2 mg). In breath-actuated DPIs, lung deposition generally falls with decreasing peak inhaled £ow rate, as the shear forces needed either to de-aggregate drug particles, or to separate drug from larger lactose carrier particles, are reduced. However, the e¡ect of £ow rate may be minimised in the MAGhaler, as the actuation process is intended to result in dose micronisation in situ.
In order to put the MAGhaler data into context, we have compared them with a range of other DPIs inTable 4, in terms of the following parameters: (a) whole lung deposition as % delivered dose with maximal inspiratory e¡ort (b) C of V of lung deposition with maximal inspiratory e¡ort, and (c) the ratio of lung deposition with approximately half maximal inspiratory e¡ort to that with maximal inspiratory e¡ort. These data were taken from studies carried out in our unit with other breath-actuated DPIs. Table 3 shows that the MAGhaler was among the more e⁄cient devices in terms of the numerical value of lung deposition. Additionally, lung deposition was highly reproducible, and relatively inhaled £ow rate independent. It is probable that this good performance re£ects properties of both device and formulation. Of the devices compared, Taifun (16), Turbuhaler (17), Novolizer (18) and Pulvinal (19) contain freely £owing powder formulations dispensed from reservoirs, while Spinhaler (20) contains the drug powder in gelatine capsules. The formulation used in the Ultrahaler (8) has some similarities to that in the MAGhaler, as the powder is compressed into a ring-shaped block, from which doses are metered. Drug deposition data that varies little with inspiratory e¡ort has also been reported previously for other breath-actuated DPIs (16, 21) , and for a DPI where the powder is dispersed by an internal electric motor (22) .However, when the e¡ect of inspiratory e¡ort upon drug delivery is very marked, therapeutic response may be reduced (23) .
The relative £ow independence of the MAGhaler should be especially useful in groups of patients who have di⁄culty inhaling maximally, which could include young children, the elderly, and patients with severe respiratory impairment (15) . By producing relatively high, relatively reproducible and relatively inhalation £ow-independent drug delivery to the lung, the MAGhaler should be a valuable addition to the range of DPI devices available for inhalation therapy, not just for salbutamol, but for a much wider range of drugs that can be formulated as dry powders. 
